Price
619.05
-4.51%52W Range
Market Cap
₹2,975.79 Cr
Traded: ₹29.02 Cr (0.98%) 0.0x
Free Float: ₹970.11 Cr (2.99% of FF traded)
Volume · 60D trend
4.56 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -3.0% | -2.0% | -- | +27.0% | Accelerating |
| ROE | -- | -7.0% | -12.0% | -- | -- | Decelerating |
| Return | -- | -12.0% | +32.0% | +21.0% | -- | Stable |
| Profit | -- | -- | +25.0% | -- | +638.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Sep 2026PDF ↗ | Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 417 | 382 | 387 | 349 | 314 | 319 | 273 | 300 | 347 | 363 | 299 | 212 | 425 | 352 | 381 | 395 | 338 |
| Expenses | 340 | 320 | 330 | 312 | 279 | 262 | 228 | 243 | 286 | 322 | 290 | 374 | 388 | 333 | 332 | 350 | 311 |
| Operating Profit | 77 | 62 | 58 | 37 | 35 | 57 | 45 | 58 | 61 | 42 | 10 | -162 | 38 | 19 | 49 | 45 | 28 |
| Other Income | -4 | 3 | 6 | -7 | 0 | 1 | 6 | 1 | 0 | 1 | -120 | -62 | -4 | 2 | 5 | 7 | 4 |
| Interest | 18 | 22 | 28 | 22 | 21 | 24 | 29 | 27 | 28 | 31 | 31 | 25 | 24 | 25 | 22 | 24 | 22 |
| Depreciation | 27 | 27 | 26 | 26 | 24 | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 26 | 26 | 26 | 28 | 29 |
| Profit Before Tax | 28 | 16 | 10 | -17 | -10 | 11 | -2 | 8 | 8 | -13 | -167 | -275 | -17 | -29 | 5 | 1 | -19 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 53.0% | 0.0% | 0.0% | -35.0% | 25.4% | 22.0% | -48.0% |
| Net Profit | 28 | 16 | 10 | -17 | -10 | 11 | -2 | 8 | 8 | -13 | -255 | -275 | -17 | -19 | 4 | 0 | -10 |
| Exceptional Items | -5 | 0 | 1 | -7 | 0 | 0 | 0 | 0 | 0 | 0 | -122 | -63 | -5 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 5.9 | 3.4 | 2.6 | -4.8 | -2.8 | 2.9 | -0.6 | 2.2 | 2.2 | -3.7 | -53.2 | -57.4 | -3.6 | -4.1 | 0.8 | 0.1 | -2.1 |
| Sales Growth (YoY) | 32.8% | 19.8% | 41.8% | 16.3% | -9.5% | -12.1% | -8.7% | 41.5% | -18.4% | 3.1% | -21.4% | -46.3% | 25.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 9.2% | -1.3% | 10.9% | 11.2% | -1.6% | 16.9% | -9.0% | -13.5% | -4.4% | 21.4% | 41.0% | -50.1% | 20.7% | -7.5% | -3.6% | 16.9% | -- |
| OP Growth (YoY) | 120.0% | 8.8% | 28.9% | -36.2% | -42.6% | 35.7% | 350.0% | 135.8% | 60.5% | 121.1% | -79.5% | -460.0% | 35.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | 24.2% | 6.9% | 56.8% | 5.7% | -38.6% | 26.7% | -22.4% | -4.9% | 45.2% | 320.0% | 106.2% | -526.3% | 100.0% | -61.0% | 8.4% | 60.7% | -- |
| Profit Growth (YoY) | 426.0% | 55.0% | 516.0% | -232.0% | -226.0% | 178.0% | 99.0% | 104.0% | 167.0% | 31.0% | -5359.0% | -47338.0% | -20.0% | -19.0% | 19.0% | 100.0% | -133.0% |
| EPS Growth (YoY) | 310.0% | 16.1% | 556.9% | -315.2% | -225.7% | 177.8% | 98.9% | 103.9% | 162.0% | 8.1% | -6834.2% | -63833.3% | -72.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 73.4% | 27.6% | 155.0% | -72.8% | -195.9% | 601.7% | -125.9% | 0.9% | 159.4% | 93.0% | 7.3% | -1502.2% | 12.0% | -615.2% | 777.8% | 104.3% | -- |
| OP Margin | 18.5% | 16.2% | 15.0% | 10.6% | 11.2% | 17.9% | 16.5% | 19.3% | 17.6% | 11.6% | 3.3% | -76.4% | 8.9% | 5.4% | 12.8% | 11.4% | 8.3% |
| Net Margin | 6.7% | 4.2% | 2.6% | -4.9% | -3.2% | 3.5% | -0.7% | 2.7% | 2.3% | -3.6% | -85.3% | -129.7% | -4.0% | -5.4% | 1.0% | 0.0% | -3.0% |
| Material Cost % | 51.0% | 51.0% | 51.0% | 53.0% | 49.0% | 46.0% | 43.0% | 45.0% | 50.0% | 55.0% | 53.0% | 102.0% | 56.0% | 54.0% | 51.0% | 54.0% | 56.0% |
| Employee Cost % | 14.0% | 15.0% | 14.0% | 16.0% | 18.0% | 17.0% | 19.0% | 17.0% | 15.0% | 15.0% | 19.0% | 30.0% | 15.0% | 17.0% | 16.0% | 15.0% | 16.6% |
| P/S | 1.94 | 2.18 | 1.87 | 1.46 | 1.39 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 87.56 | -- | -- | -- | 259.66 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.07 | 2.49 | 2.04 | 1.46 | 1.33 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Solara Active Pharma Sciences Limited has informed the Exchange regarding the copy of Newspaper publication informing about Final Reminder-cum-Forfeiture Notice for the payment of First ....
Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders ....
Solara Active Pharma Sciences Limited has informed the Exchange regarding the copy of the Newspaper publication providing extract of the unaudited Financial Results (Standalone and Consolidated) ....
Monitoring Agency Report for the quarter ended September 30, 2026
Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026
Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 2026
Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA ....
Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options.
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....
Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 2024
Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, October 16, 2026, at 4.00 PM IST to discuss the Company''s ....
Solara Active Pharma has informed the Exchange regarding the ESG Rating received from Crisil ESG Rating & Analytics Limited
Solara Active Pharma Sciences Limited has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended ....
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/10/2026 ,inter alia, to consider and approve unaudited financial ....
Update on approval of Final Reminder cum Forfeiture Notice for payment of outstanding call money.
Solara Active Pharma Sciences Limited has informed the exchange regarding the Voting Results and the Scrutinizer''s report of the Ninth Annual General Meeting
Solara Active Pharma Sciences Limited has informed the Exchange regarding the Proceedings of Ninth Annual General Meeting held on September 18, 2026.
Solara Active Pharma Sciences Limited has informed the exchange about intimation in connection with the receipt of Rectification Order
Newspaper publication regarding the completion of dispatch of 9th AGM Notice and Annual report
Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of Ninth Annual General Meeting (AGM) of the Company scheduled to be held on Friday, September 18, 2026
Annual Report for the financial year ended March 31, 2026
Business Responsibility and Sustainability Reporting for the financial year 2025-26.
Solara Active Pharma Sciences Limited has informed the stock exchange regarding the Newspaper publication with respect to the Ninth Annual General Meeting.
Conversion of Partly paid-up Rights Equity Shares into fully paid-up Equity shares in relation to the rights issue by the Company, upon receipt of Call Monies, as applicable.
Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 2250 equity shares pursuant to exercise of ESOP options
Solara Active Pharma Sciences Limited has informed the exchange regarding the update with respect to our intimation dated July 23, 2026, regarding appointment of Chief Information Officer ....
Solara Active Pharma Sciences Limited has informed the exchange about the copy of the Newspaper publication providing extract of the unaudited Financial Results (Standalone and Consolidated) ....
Solara Active Pharma Sciences Limited has informed the exchange regarding submission of Machine Readable copy of Financial results for the quarter ended June 30, 2026
Solara Active Pharma Sciences Limited has informed the exchange regarding, inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....
Solara Active Pharma Sciences Limited has informed the exchange about the Audio Recording of the Q1 FY 27 Earnings call held on July 23, 2026, at 16.00 IST
Monitoring Agency Report for the quarter ended June 30, 2026
Solara Active Pharma Sciences Limited has informed the exchange that there is no Deviation and Variation of funds raised through Rights Issue for the quarter ended June 30, 2026
Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 2250 Equity Shares pursuant to exercise of ESOP options.
Solara Active Pharma Sciences Limited has informed the exchange regarding the appointment of Mr. Ajit Manocha as Chief Information Officer (CIO) and designated him as Senior Management ....
Solara Active Pharma Sciences Limited has informed the exchange regarding the Press Release dated July 23, 2026, titled- Solara reports strong Q1''27 Base business performance with continued ....
Solara Active Pharma Sciences Limited has informed the exchange regarding the Press Release dated July 23, 2026, titled - Solara reports Strong Q1''27 Base business performance with Continued ....
Solara Active Pharma Sciences Limited has informed the exchange regarding, inter alia, to consider and approve the unaudited Standalone and Consolidated financial results for the quarter ....
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve the unaudited ....
Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Thursday, July 23, 2026 at 4.00 PM IST to discuss the Company''s ....
The Company has informed the exchange about the Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30, 2026
Copy of newspaper publication with respect to Final Reminder cum Forfeiture Notice for payment of Call money to partly paid equity shareholders
Solara Active Pharma Sciences Limited has informed the exchange about the approval of the Reminder - cum- Forfeiture Notice, by the Rights Issue Committee members, to be issued to the partly ....
Copy of newspaper advertisement regarding dispatch of notices to shareholders for the transfer of equity shares to the IEPF in respect of the unclaimed and unpaid dividend for the financial ....
Dispatch of notices regarding the transfer of equity shares to the IEPF in respect of the unclaimed and unpaid dividend for the financial year 2018-19
Intimation regarding closure of Trading Window for the quarter ended June 30 2026
Solara Active Pharma Sciences Limited has informed the Stock Exchange regarding Credit Rating received from Crisil Ratings Limited
Allotment of 70,000 Equity Shares pursuant to exercise of Options under Solara Employee Stock Option Plan 2024
Allotment of 2,250 Equity shares pursuant to exercise of Options under Solara Employee Stock Option Plan 2018
Clarification in relation to the Email received from BSE on June 10, 2026 on Volume movement.
Annual Reports
9Credit Ratings
6Concalls
29Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Jul 2024
31 Jul 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Jul 2021
31 Jul 2021Apr 2021
30 Apr 2021Jan 2021
31 Jan 2021Oct 2020
31 Oct 2020Sep 2020
30 Sept 2020May 2020
31 May 2020Jan 2020
31 Jan 2020Oct 2019
31 Oct 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Jan 2019
31 Jan 2019Nov 2018
30 Nov 2018Jul 2018
31 Jul 2018Held by ETFs
1 ETFs hold SOLARA · sorted by weight
Held by Mutual Funds
3 schemes hold SOLARA · sorted by weight